Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

Policy swings have made it a slippery year for pharma ...

Emil Kongshøj Larsen, Executive Vice President for International Operations at Novo Nordisk, talks to BT about India’s role ...

Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...

VanEck Pharmaceutical ETF is rated a Buy with stability, earnings visibility, and resilience across volatile market cycles.

Doctors and groups representing employers said they’re increasingly hearing about companies cutting weight loss drugs out of ...

On December  15, 2025, UBS reaffirmed its Neutral (Hold) rating on NVO with an unchanged price target of DKK 295, reflecting ...

U.S. President Donald ​Trump ⁠in July sent letters to 17 drugmakers urging them to slash prices. Pfizer and AstraZeneca first ...

Inflammatory bowel disease and elevated BMI may play causal roles in hidradenitis suppurativa, results of a Mendelian ...